RecruitingPhase 1NCT07361562
Rare condition
Small cell lung cancer
1,513
studies recruiting now
as of 7 Sept 2026
9,651
studies registered in total
as of 7 Sept 2026
23
countries with a recruiting site
as of 7 Sept 2026
29 May 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNot applicableNCT05990946
Smartphone-based Remote Symptom Monitoring to Improve Postoperative Rehabilitation Exercise Adherence After Video-assisted Thoracic Surgery (VATS) for Lung Cancer
RecruitingPhase 1 / Phase 2NCT07468071
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
RecruitingPhase 2 / Phase 3NCT06712316
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
RecruitingPhase 1NCT07613723
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 1,513 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Small cell lung cancer study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Small cell lung cancer
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (RB1, TP53, TP73).
Treatments being studied
10 approved treatments and 151 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Tarlatamab (Imdelltra)Approved: TopotecanApproved: Durvalumab (Imfinzi)Approved: TrilaciclibApproved: Topotecan Hydrochloride (Evotopin)Approved: Atezolizumab (Atezolizumab component of tecentriq hybreza)Approved: Lurbinectedin (Zepsyre)Approved: SerplulimabApproved: Etoposide (Etoposide)Approved: Trilaciclib Dihydrochloride (Cosela)
Phase 3Irinotecan Hydrochloride (Campto)
Phase 3Pemetrexed (Alimta)
Phase 3Irinotecan
Phase 3Ivonescimab
Phase 3Carboplatine
Phase 3Tislelizumab (Tevimbra)
Phase 3Catequentinib
Phase 3Carboplatin (Carboplatin)
+ 143 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).